Global Inflammatory Bowel Disease Therapeutics Market to Reach US $4.3 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Inflammatory Bowel Disease Therapeutics market. The world market for Inflammatory Bowel Disease (IBD) Therapeutics is projected to exceed US$4.3 billion by the year 2015. This is primarily driven by prevalence and incidence in the key markets of North America and Europe. Increasing preference for high priced biologics, as against conventional treatment options, is further driving the global market. Besides, factors such as unmet medical needs and an extensive pipeline of drugs with superior efficacy keep growth prospects optimistic.

Inflammatory Bowel Disease Therapeutics: A Global Strategic Business report

With growing incidence and prevalence of Inflammatory Bowel Disease (IBD), especially in temperate regions of North America and Europe, the IBD therapeutics market is expected to grow in near future. The two forms of inflammatory bowel diseases, namely Ulcerative colitis and Crohn's disease, are considered as a type of autoimmune disorders. Key factors driving growth of this sector include increasing use of biologics, as against conventional treatment options. These biologic drugs are usually priced higher than the conventional drugs, which continue to drive revenues for manufacturers. Besides, factors such as unmet medical needs and an extensive pipeline of drugs with superior efficacy keep growth prospects optimistic.

Over 2 million people across Europe, the US and Japan suffer from one of the two inflammatory bowel diseases, as stated by the new market research report on inflammatory bowel disease therapeutics market. The number is expected to grow considerably in near future, acting as a major driving force for the IBD therapeutics market. Prevalence of IBD is higher in developed countries of Europe, Americas and Japan, as compared to rest of world. The disease still lacks awareness among the population, as most people affected with the disease keep it low profile due to the nature of symptoms and social stigma. This in turn results in impassive seriousness among the population about the disease.

Key players profiled in the report include Abbott Laboratories, GlaxoSmithKline plc, Johnson & Johnson, Merck Serono, Millennium Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Shire plc, and UCB SA, among others.

The report titled "Inflammatory Bowel Disease Therapeutics: A Global Strategic Business report" announced by Global Industry Analysts, Inc., provides a comprehensive review of industry overview, product overview, product introductions/innovations, profiles of major players, and recent industry activity. The report analyzes market data and analytics in terms of value sales of therapeutics by the following disease types - Crohn's Disease and Ulcerative Colitis.

For more details about this comprehensive market research report, please visit -

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website